REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. - Wikidata - awgldk - TriplyDB

REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.

REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.

http://www.wikidata.org/entity/Q37602536

about

Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants Going viral: a review of replication-selective oncolytic adenoviruses Oncolytic virotherapy for human malignant mesothelioma: recent advances Chemovirotherapy: combining chemotherapeutic treatment with oncolytic virotherapy Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances Oncolytic virotherapy for pediatric malignancies: future prospects Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors Serotype-Specific Killing of Large Cell Carcinoma Cells by Reovirus.A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway.A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer.Naturally occurring reoviruses for human cancer therapy.Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.Oncolytic reovirus synergizes with chemotherapeutic agents to promote cell death in canine mammary gland tumor Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia.Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy.Reovirus in cancer therapy: an evidence-based review Reolysin is a novel reovirus-based agent that induces endoplasmic reticular stress-mediated apoptosis in pancreatic cancer.Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.Reovirus: a targeted therapeutic--progress and potential.Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer.Multispectral imaging: a review of its technical aspects and applications in anatomic pathology.Oncolytic virus therapies.Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus.The oncolytic virus, pelareorep, as a novel anticancer agent: a review.HIF-1α downregulation and apoptosis in hypoxic prostate tumor cells infected with oncolytic mammalian orthoreovirus.Asynchronous leptomeningeal carcinomatosis from pancreatic cancer: a case report and review of the literature.Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy.Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.

P2860

Q24596171-EDB8A942-04EF-4546-B207-7403444B5971 Q24617027-E3E17DD7-0E31-4283-B478-BCC00B6B1C77 Q26750568-FF383147-2064-42CC-B7EA-BDBEB24A40A7 Q26752807-208303CD-67B5-48FD-8686-EB8FF848AE69 Q26775030-75F118BA-9559-433C-93E2-374AE9FB2C64 Q26775033-7F99B50E-8F30-46A6-AFCF-38BB6F19F22C Q26797520-73A2DD44-083C-438B-ACA1-AA5F29D4F37F Q26826590-0D5951C9-C378-460D-ACA9-2F2DB64B9B43 Q26852345-F5395071-FEFB-41AC-ABAD-4A094B59481E Q26863779-625D9DE8-F71B-4707-B8C1-7977D7EE63B9 Q28069358-08A2C1C3-0318-4E14-9494-8E7D1C4C0901 Q28086999-04B0D4F3-A674-4AF0-B8C8-9DC96AD695F0 Q32183285-F6486EDB-0B41-4A30-A451-DF3F9A1739F3 Q33418048-42CCBBD4-D9AE-41EB-9EA7-013203D7883B Q33924515-F87F1198-4031-4675-A093-8C1F9AB2AB2A Q34393001-11EA0381-D467-403F-A326-6672BC35F27C Q35224368-29ABC356-2C46-418D-9B4B-11AC67BCB855 Q35596563-FE7C99FA-53F4-4473-9386-9B291C3879C9 Q35686522-89C0EA9A-3CAA-4EE9-AFD5-4ED8CD2C17A7 Q36078485-2D19CF2B-67E1-4BC2-A2E5-A6A9296A72CC Q36298608-A0D10C70-9987-4F2E-A989-E8A92686DF94 Q36390114-0CFAFDEC-5DF7-4EAF-924F-23945A53D21D Q36574519-AA895A6B-369B-4CE3-89DD-C2196DB9FDB1 Q36582819-D9680F17-83FD-43C7-B6F5-68BE58A8FC35 Q36766032-01C2CCCD-E025-45D3-B90E-39449F6DDABF Q36766052-678A5959-8150-4A3A-80BD-4160E3126A2E Q37031909-DB9A8856-B2C3-4AC3-8AF2-F1A4CB977142 Q37062074-0851B87A-A61B-40BF-B964-C32006C9658B Q37347236-BE6FDC0B-4F22-48D6-8BED-78F8F246FCCB Q37360608-305A73E1-1F63-454A-9585-9DD0BE0A0EAA Q37477574-D4335867-06DF-42DF-A34B-1BF8152C8CF3 Q38058884-08853587-5713-48CE-8B06-91C622BDF2B6 Q38152999-8E6BD4C7-254A-4CDE-BD3E-1CADDFCC8A95 Q38162950-3D7FA877-C3FE-4D8D-88A1-FA6B341EC46B Q38315523-C8F625D8-DFD2-47A9-B126-52682F0A704D Q38360781-896DBCF1-1141-431B-8340-3CB772AAE1F1 Q38458133-A84FDDFC-397A-458C-AAF6-1AF7B2776954 Q38548938-A0A765DB-56AC-4624-884E-9F4D55C4C8D8 Q38647883-56CB59E6-9BA7-4032-A5A1-BA0F4DEEE484 Q38653084-940DC60F-B267-424C-A961-5E5E97730B5C

P2860

REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.

http://www.wikidata.org/entity/Q37602536

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 06 October 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

REO-10: a phase I study of int ...... patients with advanced cancer.

@en

REO-10: a phase I study of int ...... patients with advanced cancer.

@en-gb

REO-10: a phase I study of int ...... patients with advanced cancer.

@nl

type

label

REO-10: a phase I study of int ...... patients with advanced cancer.

@en

REO-10: a phase I study of int ...... patients with advanced cancer.

@en-gb

REO-10: a phase I study of int ...... patients with advanced cancer.

@nl

prefLabel

REO-10: a phase I study of int ...... patients with advanced cancer.

@en

REO-10: a phase I study of int ...... patients with advanced cancer.

@en-gb

REO-10: a phase I study of int ...... patients with advanced cancer.

@nl

P1433

Q37602536-08AE36E7-3B9D-4143-9461-455DF595FADF

P1476

Q37602536-244D701E-22B6-43C4-A1AD-BA1E0E0E323A

P2093

Q37602536-14B251B8-3638-43EC-B79E-E4A575DBB3B0

Q37602536-1FAB4D73-76CE-4F75-B685-BACBBD51BE79

Q37602536-209CAB7A-EFF0-4E5E-BD86-481AFEB9D64F

Q37602536-393777CA-EC9C-421F-A7EB-E351D296F9B2

Q37602536-45B8B177-855E-427D-9E3C-E4C628D2C829

Q37602536-65DFD037-05DD-4AB2-B96C-BE46826ABBD9

Q37602536-7F6CF2A8-ED1A-4778-83A7-228144640E5E

Q37602536-9C66DB00-EE49-43EE-9DFD-FF08C6732DD7

Q37602536-A4496FFD-E209-4FF1-981D-903260843188

Q37602536-C165D4C4-3B1E-48D5-AC3A-7A5A284467E7

P2860

Q37602536-020110BA-B044-4D28-AAC8-F1335579C9D7

Q37602536-07033117-51AD-4770-95A0-53759E946400

Q37602536-0F50CC9C-1A1E-447F-9CCB-999C0C797527

Q37602536-1805DC5A-7B1E-4808-B023-5017652E4FCE

Q37602536-1ACACA00-5955-47D8-9FA3-3266D0A76D5D

Q37602536-1F8CC267-BBD4-4417-847C-39D9D35F13F7

Q37602536-20BE737A-BA19-4560-904F-05B7033A15E1

Q37602536-2AB924DE-F3D6-4527-86D6-C7259C31EC1D

Q37602536-365402E2-FE61-4CC9-8232-5EE726B3FE34

Q37602536-422AB074-F7F0-4E19-BD08-62992BAD652E

P304

Q37602536-B23D4F14-2205-4EA4-B1C8-7D80AC2BA94F

P31

Q37602536-FE169F5D-20A4-40BA-8859-FBE3DBD04FAF

P356

Q37602536-09C876C0-C978-41A1-A17F-46A9E8398D70

P407

Q37602536-FB80C1CB-7C93-4FAC-9AAB-890A76363519

P433

Q37602536-3302823D-7F9B-4DD2-B67F-7E07781714DA

P478

Q37602536-09C98C78-2B7D-4CF3-8E32-B7465914EFA4

P50

Q37602536-32CF86C1-4005-4BFF-B221-189E0B14219B

P577

Q37602536-CAB00A77-F3D5-4110-98C2-3A7DC8D51398

P698

Q37602536-C575515D-B98D-41A8-90C1-0D52D018BC85

P921

Q37602536-D33E53EA-E5B6-44A8-BCA3-C19CBA4FCBAC

P932

Q37602536-58420F16-9C54-4ABA-A02D-CA022B194E27

P356

1078-0432.CCR-10-1233

P1433

Clinical Cancer Research

P1476

REO-10: a phase I study of int ...... patients with advanced cancer.

@en

P2093

Andrew Protheroe

http://www.w3.org/2001/XMLSchema#string

Charles Comins

http://www.w3.org/2001/XMLSchema#string

Christine M White

http://www.w3.org/2001/XMLSchema#string

David E Cohn

http://www.w3.org/2001/XMLSchema#string

Gerard Nuovo

http://www.w3.org/2001/XMLSchema#string

Hardev S Pandha

http://www.w3.org/2001/XMLSchema#string

James Spicer

http://www.w3.org/2001/XMLSchema#string

Karl L Mettinger

http://www.w3.org/2001/XMLSchema#string

Katie Twigger

http://www.w3.org/2001/XMLSchema#string

Kevin J Harrington

http://www.w3.org/2001/XMLSchema#string

P2860

Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells

The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus

Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

ras oncogenes in human cancer: a review

The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer (Review).

Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus.

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.

Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic.

The preferential cytotoxicity of reovirus for certain transformed cell lines.

P304

5564-5572

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-10-1233

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-10-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20926400

http://www.w3.org/2001/XMLSchema#string

P921

P932

3934355

http://www.w3.org/2001/XMLSchema#string